OptimizeRx Co. (NASDAQ:OPRX) Receives $9.06 Average PT from Analysts

OptimizeRx Co. (NASDAQ:OPRX) has been given a consensus recommendation of “Moderate Buy” by the nine research firms that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $9.06.

OPRX has been the subject of a number of analyst reports. Stephens initiated coverage on OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price objective on shares of OptimizeRx in a research note on Thursday, February 6th. Lake Street Capital reissued a “buy” rating and issued a $11.00 target price on shares of OptimizeRx in a research note on Tuesday, December 24th. B. Riley raised OptimizeRx to a “strong-buy” rating in a research note on Wednesday, March 12th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th.

OptimizeRx Stock Down 1.8 %

Shares of OptimizeRx stock opened at $8.63 on Wednesday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $14.13. The business has a fifty day simple moving average of $5.84 and a 200 day simple moving average of $5.94. The stock has a market cap of $158.97 million, a PE ratio of -6.49 and a beta of 1.31.

Insider Transactions at OptimizeRx

In related news, Director James Paul Lang bought 321,408 shares of the company’s stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the acquisition, the director now owns 389,452 shares of the company’s stock, valued at approximately $2,959,835.20. The trade was a 472.35 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.10% of the stock is owned by insiders.

Institutional Trading of OptimizeRx

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Delta Investment Management LLC bought a new stake in OptimizeRx during the fourth quarter worth about $146,000. Squarepoint Ops LLC raised its holdings in OptimizeRx by 298.8% during the fourth quarter. Squarepoint Ops LLC now owns 41,712 shares of the company’s stock worth $203,000 after acquiring an additional 31,252 shares in the last quarter. Tang Capital Management LLC bought a new stake in OptimizeRx in the fourth quarter valued at approximately $1,075,000. Graham Capital Management L.P. bought a new stake in OptimizeRx in the fourth quarter valued at approximately $81,000. Finally, D. E. Shaw & Co. Inc. raised its stake in OptimizeRx by 12.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 295,717 shares of the company’s stock valued at $1,437,000 after buying an additional 32,062 shares during the period. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.